| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Reviews |
Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland
Mesothelin is a differentiation antigen present on normal mesothelial cells and overexpressed in several human tumors, including mesothelioma and ovarian and pancreatic adenocarcinoma. The mesothelin gene encodes a precursor protein that is processed to yield the 40-kDa protein, mesothelin, attached to the cell membrane by a glycosylphosphatidyl inositol linkage and a 31-kDa shed fragment named megakaryocyte-potentiating factor. The biological function of mesothelin is not known. Mesothelin is a promising candidate for tumor-specific therapy, given its limited expression in normal tissues and high expression in several cancers. SS1(dsFv)PE38 is a recombinant anti-mesothelin immunotoxin that is undergoing clinical evaluation in patients with mesothelin-expressing tumors. There is evidence that mesothelin is an immunogenic protein and could be exploited as a therapeutic cancer vaccine. A soluble mesothelin variant has been identified and could be a useful tumor marker for malignant mesotheliomas.
This article has been cited by other articles:
|
|
 |
|
  Y. Feng, X. Xiao, Z. Zhu, E. Streaker, M. Ho, I. Pastan, and D. S. Dimitrov A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity Mol. Cancer Ther., May 1, 2009; 8(5): 1113 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Tsao, I. Wistuba, J. A. Roth, and H. L. Kindler Malignant Pleural Mesothelioma J. Clin. Oncol., April 20, 2009; 27(12): 2081 - 2090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Carpenito, M. C. Milone, R. Hassan, J. C. Simonet, M. Lakhal, M. M. Suhoski, A. Varela-Rohena, K. M. Haines, D. F. Heitjan, S. M. Albelda, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains PNAS, March 3, 2009; 106(9): 3360 - 3365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Xuan, Y.-J. Li, G. Liu, Y. Ben-David, and M. C. Archer Interleukin-24 Induces Expression of {beta}4 Integrin but Suppresses Anchorage-Independent Growth of Rat Mammary Tumor Cells by a Mechanism That Is Independent of {beta}4 Mol. Cancer Res., March 1, 2009; 7(3): 433 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bidlingmaier, J. He, Y. Wang, F. An, J. Feng, D. Barbone, D. Gao, B. Franc, V. C. Broaddus, and B. Liu Identification of MCAM/CD146 as the Target Antigen of a Human Monoclonal Antibody that Recognizes Both Epithelioid and Sarcomatoid Types of Mesothelioma Cancer Res., February 15, 2009; 69(4): 1570 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Bharadwaj, M. Li, C. Chen, and Q. Yao Mesothelin-Induced Pancreatic Cancer Cell Proliferation Involves Alteration of Cyclin E via Activation of Signal Transducer and Activator of Transcription Protein 3 Mol. Cancer Res., November 1, 2008; 6(11): 1755 - 1765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Du, R. Beers, D. J. FitzGerald, and I. Pastan Differential Cellular Internalization of Anti-CD19 and -CD22 Immunotoxins Results in Different Cytotoxic Activity Cancer Res., August 1, 2008; 68(15): 6300 - 6305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Hellstrom, E. Friedman, T. Verch, Y. Yang, J. Korach, J. Jaffar, E. Swisher, B. Zhang, G. Ben-Baruch, M. C.B. Tan, et al. Anti-Mesothelin Antibodies and Circulating Mesothelin Relate to the Clinical State in Ovarian Cancer Patients Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1520 - 1526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Johnson, F. Vito, and M. J. O'Connell Mesothelin Expression in the Leptomeninges and Meningiomas J. Histochem. Cytochem., June 1, 2008; 56(6): 579 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Alvarez, A. Corvalan, J. C. Roa, P. Argani, F. Murillo, J. Edwards, R. Beaty, G. Feldmann, S.-M. Hong, M. Mullendore, et al. Serial Analysis of Gene Expression Identifies Connective Tissue Growth Factor Expression as a Prognostic Biomarker in Gallbladder Cancer Clin. Cancer Res., May 1, 2008; 14(9): 2631 - 2638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, et al. Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal Metastases Clin. Cancer Res., April 1, 2008; 14(7): 1938 - 1946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. An, D. C. Drummond, S. Wilson, D. B. Kirpotin, S. L. Nishimura, V. C. Broaddus, and B. Liu Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies Mol. Cancer Ther., March 1, 2008; 7(3): 569 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Li, U. Bharadwaj, R. Zhang, S. Zhang, H. Mu, W. E. Fisher, F. C. Brunicardi, C. Chen, and Q. Yao Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer Mol. Cancer Ther., February 1, 2008; 7(2): 286 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Du, S. Nagata, T. Ise, M. Stetler-Stevenson, and I. Pastan FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins Blood, January 1, 2008; 111(1): 338 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hassan, V. C. Broaddus, S. Wilson, D. J. Liewehr, and J. Zhang Anti Mesothelin Immunotoxin SS1P in Combination with Gemcitabine Results in Increased Activity against Mesothelin-Expressing Tumor Xenografts Clin. Cancer Res., December 1, 2007; 13(23): 7166 - 7171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Creaney, I. van Bruggen, M. Hof, A. Segal, A. W. Musk, N. de Klerk, N. Horick, S. J. Skates, and B. W. S. Robinson Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma Chest, October 1, 2007; 132(4): 1239 - 1246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hassan, S. Bullock, A. Premkumar, R. J. Kreitman, H. Kindler, M. C. Willingham, and I. Pastan Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers Clin. Cancer Res., September 1, 2007; 13(17): 5144 - 5149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y C G. Lee Hunting for a pleural fluid test for mesothelioma: is soluble mesothelin the answer? Thorax, July 1, 2007; 62(7): 561 - 562. [Full Text] [PDF]
|
|
|
|
|
|
M. Ho, T. K. Bera, M. C. Willingham, M. Onda, R. Hassan, D. FitzGerald, and I. Pastan Mesothelin Expression in Human Lung Cancer Clin. Cancer Res., March 1, 2007; 13(5): 1571 - 1575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Hassan, R Alexander, K Antman, P Boffetta, A Churg, D Coit, P Hausner, R Kennedy, H Kindler, M Metintas, et al. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference Ann. Onc., November 1, 2006; 17(11): 1615 - 1619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ho, M. Onda, Q.-c. Wang, R. Hassan, I. Pastan, and M. O. Lively Mesothelin is shed from tumor cells. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1751 - 1751. [Full Text] [PDF]
|
|
|
|
|
|
R. Hassan, J. Williams-Gould, S. M. Steinberg, D. J. Liewehr, J. Yokokawa, K. Y. Tsang, R. J. Surawski, T. Scott, and K. Camphausen Tumor-Directed Radiation and the Immunotoxin SS1P in the Treatment of Mesothelin-Expressing Tumor Xenografts. Clin. Cancer Res., August 15, 2006; 12(16): 4983 - 4988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, L. Xiang, R. Hassan, C. H. Paik, J. A. Carrasquillo, B.-s. Jang, N. Le, M. Ho, and I. Pastan Synergistic Antitumor Activity of Taxol and Immunotoxin SS1P in Tumor-Bearing Mice Clin. Cancer Res., August 1, 2006; 12(15): 4695 - 4701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Onda, S. Nagata, M. Ho, T. K. Bera, R. Hassan, R. H. Alexander, and I. Pastan Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin. Cancer Res., July 15, 2006; 12(14): 4225 - 4231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Scherpereel, B. Grigoriu, M. Conti, T. Gey, M. Gregoire, M.-C. Copin, P. Devos, B. Chahine, H. Porte, and P. Lassalle Soluble Mesothelin-related Peptides in the Diagnosis of Malignant Pleural Mesothelioma Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1155 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Steinbach, A. Schramm, A. Eggert, M. Onda, K. Dawczynski, A. Rump, I. Pastan, S. Wittig, N. Pfaffendorf, A. Voigt, et al. Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia Clin. Cancer Res., April 15, 2006; 12(8): 2434 - 2441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. K. Sutherland, R. J. Sanderson, K. A. Gordon, J. Andreyka, C. G. Cerveny, C. Yu, T. S. Lewis, D. L. Meyer, R. F. Zabinski, S. O. Doronina, et al. Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates J. Biol. Chem., April 14, 2006; 281(15): 10540 - 10547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jimeno and M. Hidalgo Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol. Cancer Ther., April 1, 2006; 5(4): 787 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Li, T. Sai, M. Berger, Q. Chao, D. Davidson, G. Deshmukh, B. Drozdowski, W. Ebel, S. Harley, M. Henry, et al. Human antibodies for immunotherapy development generated via a human B cell hybridoma technology PNAS, March 7, 2006; 103(10): 3557 - 3562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Yen, C.-Y. Hsu, T.-L. Mao, T-C. Wu, R. Roden, T.-L. Wang, and I.-M. Shih Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous Carcinoma Clin. Cancer Res., February 1, 2006; 12(3): 827 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hassan, A. T. Remaley, M. L. Sampson, J. Zhang, D. D. Cox, J. Pingpank, R. Alexander, M. Willingham, I. Pastan, and M. Onda Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer Clin. Cancer Res., January 15, 2006; 12(2): 447 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. W. Robinson and R. A. Lake Advances in malignant mesothelioma. N. Engl. J. Med., October 13, 2005; 353(15): 1591 - 1603. [Full Text] [PDF]
|
|
|
|
|
|
J. Yokokawa, C. Palena, P. Arlen, R. Hassan, M. Ho, I. Pastan, J. Schlom, and K. Y. Tsang Identification of Novel Human CTL Epitopes and Their Agonist Epitopes of Mesothelin Clin. Cancer Res., September 1, 2005; 11(17): 6342 - 6351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Onda, M. Willingham, S. Nagata, T. K. Bera, R. Beers, M. Ho, R. Hassan, R. J. Kreitman, and I. Pastan New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA Clin. Cancer Res., August 15, 2005; 11(16): 5840 - 5846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sato, R. Hassan, D. B. Axworthy, K. J. Wong, S. Yu, L. J. Theodore, Y. Lin, L. Park, M. W. Brechbiel, I. Pastan, et al. Pretargeted Radioimmunotherapy of Mesothelin-Expressing Cancer Using a Tetravalent Single-Chain Fv-Streptavidin Fusion Protein J. Nucl. Med., July 1, 2005; 46(7): 1201 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ho, R. Hassan, J. Zhang, Q.-c. Wang, M. Onda, T. Bera, and I. Pastan Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients Clin. Cancer Res., May 15, 2005; 11(10): 3814 - 3820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Shaw, Z. E. Muminova, T. V. Strong, R. Hassan, T. Bera, M. Ho, and I. Pastan Mesothelin: A New Target for Immunotherapy Clin. Cancer Res., December 15, 2004; 10(24): 8751 - 8751. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
